Gyre Therapeutics, Inc. Debt Securities, Held-to-Maturity, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One
Gyre Therapeutics, Inc. (GYRE) had Debt Securities, Held-to-Maturity, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One of $14.06 million as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Notes › Debt Securities, Held-to-Maturity, Maturity › Debt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss, Maturity, Allocated and Single Maturity Date
us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount · last filed 2026-08-07
- 2026-06-30: Debt Securities, Held-to-Maturity, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One $14.06M.
- 2026-03-31: Debt Securities, Held-to-Maturity, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One $12.31M.
- 2025-12-31: Debt Securities, Held-to-Maturity, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One $15.36M.
- 2025-09-30: Debt Securities, Held-to-Maturity, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One $19.65M.
| Period end | Debt Securities, Held-to-Maturity, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One |
|---|---|
| 2026-06-30 | $14.06M 10-Q · filed 2026-08-07 |
| 2026-03-31 | $12.31M 10-Q · filed 2026-05-08 |
| 2025-12-31 | $15.36M 10-K · filed 2026-03-13 |
| 2025-09-30 | $19.65M 10-Q · filed 2025-11-07 |
| 2025-06-30 | $17.87M 10-Q · filed 2025-08-11 |
| 2025-03-31 | $14.85M 10-Q · filed 2025-05-09 |
| 2024-12-31 | $14.86M 10-K · filed 2025-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |